Valuation: Alkermes plc

Market Cap 821.87Cr 714.45Cr 665Cr 610.55Cr 1.15TCr 78TCr 1.17TCr 7.84TCr 3.08TCr 39TCr 3.09TCr 3.02TCr 1,31000Cr P/E 2026 *
-96.2x
P/E 2027 * 67.4x
Enterprise Value 896.26Cr 779.12Cr 725.19Cr 665.82Cr 1.26TCr 86TCr 1.28TCr 8.55TCr 3.35TCr 43TCr 3.37TCr 3.29TCr 1,42800Cr EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.57x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week-7.37%
1 month-10.24%
3 months+46.76%
6 months+40.13%
Current year+75.09%
1 week 47.66
Extreme 47.66
52.51
1 month 47.66
Extreme 47.66
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

Compliance Officer

-2,034 0.0012%
01/07/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
12/06/26 Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%-7.37%+84.52%+75.28% 821.87Cr
-1.40%+2.59%-1.71%+12.94% 4.85TCr
-2.41%-0.90%+411.96%+472.09% 3.99TCr
-1.16%+12.96%+28.81%+7.27% 3.87TCr
-1.88%-3.03%+5.69%+66.52% 3.51TCr
-1.74%+5.12%+14.44%+44.64% 2.98TCr
-0.21%-4.04%+36.40%+126.06% 1.61TCr
-2.85%-3.92% - - 1.61TCr
-0.64%+2.65%+3.40%+14.79% 1.36TCr
-1.19%-1.32%-1.73%-34.97% 1.26TCr
Average -1.56%+0.21%+64.64%+87.18% 2.59TCr
Weighted average by Cap. -1.61%+1.74%+79.94%+106.39%

Financials

2026 *2027 *
Net sales 182.49Cr 158.64Cr 147.66Cr 135.57Cr 256.01Cr 17TCr 259.97Cr 1.74TCr 683.09Cr 8.67TCr 685.36Cr 670.3Cr 29TCr 194.46Cr 169.04Cr 157.34Cr 144.46Cr 272.8Cr 19TCr 277.03Cr 1.85TCr 727.9Cr 9.24TCr 730.31Cr 714.26Cr 31TCr
Net income -8.99Cr -7.82Cr -7.28Cr -6.68Cr -13Cr -858.37Cr -13Cr -86Cr -34Cr -427.34Cr -34Cr -33Cr -1.43TCr 12Cr 10Cr 9.73Cr 8.94Cr 17Cr 1.15TCr 17Cr 114.72Cr 45Cr 571.66Cr 45Cr 44Cr 1.92TCr
Net Debt 74Cr 65Cr 60Cr 55Cr 104.36Cr 7.1TCr 105.98Cr 709.52Cr 278.46Cr 3.54TCr 279.39Cr 273.25Cr 12TCr 67Cr 58Cr 54Cr 50Cr 94Cr 6.4TCr 95Cr 638.95Cr 250.77Cr 3.18TCr 251.6Cr 246.07Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
31/26/31 $48.99 -2.08% 16,24,487
30/26/30 $50.03 +3.50% 23,03,338
29/26/29 $48.34 -4.28% 41,49,635
28/26/28 $50.50 -4.23% 28,75,996
27/26/27 $52.73 -0.30% 14,02,922
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.99USD
Average target price
56.00USD
Spread / Average Target
+14.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock